RJA
RVPH

Raymond James & Associates’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Raymond James & Associates’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,650
Closed -$52K – 4046
2022
Q3 		$52K Buy
1,650
+650
+65% +$18K ﹤0.01% 3702
2022
Q2 		$22K Buy
1,000
+300
+43% +$10.5K ﹤0.01% 3866
2022
Q1 		$34K Buy
+700
New +$27.9K ﹤0.01% 3950

Other funds holding RVPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Raymond James & Associates's RVPH Position: Q4 2022 in Review

Raymond James & Associates sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2022, closing a stake of 1,650 shares — an estimated $52K sold.

Raymond James & Associates first reported a position in RVPH in Q1 2022 and held it in 3 quarters. The position peaked at $52K in Q3 2022. 23 funds tracked by Wall St. Rank hold RVPH as of Q4 2022.

  • Raymond James & Associates reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,650 REVIVA PHARMA HLDGS INC shares in Q4 2022, an estimated $52K.
  • Raymond James & Associates first reported a position in REVIVA PHARMA HLDGS INC in Q1 2022 and held it in 3 quarters.
  • Raymond James & Associates's REVIVA PHARMA HLDGS INC position peaked at $52K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.